CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor
Jiaxuan Li, Jingya Sun, Weisong Tan, Guoqi Li, Wenjie Xiao, Jiajun Wu, Wei Yang, Changqing Chen, Yang Li, Jiakuan Liu, Yuanyu Liu, Dong Liu, Xiao-hua Chen, Rujian Zhu, Ruimin Huang, Jun Yan · 2026
Read CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor by Jiaxuan Li, Jingya Sun, Weisong Tan, Guoqi Li, Wenjie Xiao, Jiajun Wu, Wei Yang, Changqing Chen, Yang Li, Jiakuan Liu, Yuanyu Liu, Dong Liu, Xiao-hua Chen, Rujian Zhu, Ruimin Huang, Jun Yan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13295117.txt.
Description
Jiaxuan Li and a large team pair a protein degrader with an approved drug against stubborn prostate cancer in a 2026 study. The PARP blocker olaparib helps only patients with BRCA gene faults, leaving most castration-resistant cases without that option. Forcing a BRCA-like state could widen its reach.
Data from 921 patients across six public sets flagged the regulator CDK9 as raised in advanced disease. The degrader D45 lowered repair gene activity, piled up DNA damage, and made cancer cells behave as if BRCA-faulty. Giving D45 before olaparib killed more cells, shrank mouse tumours, and held up in human tissue pieces, with bearable side effects.
Catalog record
| CREATOR | Jiaxuan Li, Jingya Sun, Weisong Tan, Guoqi Li, Wenjie Xiao, Jiajun Wu, Wei Yang, Changqing Chen, Yang Li, Jiakuan Liu, Yuanyu Liu, Dong Liu, Xiao-hua Chen, Rujian Zhu, Ruimin Huang, Jun Yan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44227 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |